PAS
TCRX icon

Point72 Asia (Singapore)’s TScan Therapeutics TCRX Stock Holding History

Point72 Asia (Singapore)’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$26.5K Sell
14,535
-14,535
-50% -$25.7K ﹤0.01% 661
2025
Q2 		$42.2K Buy
+29,070
New +$42K 0.01% 625
2024
Q2 		– Sell
-19,736
Closed -$157K – 1479
2024
Q1 		$157K Buy
+19,736
New +$124K 0.04% 515

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

Point72 Asia (Singapore)'s TCRX Position: Q3 2025 in Review

Point72 Asia (Singapore) reduced its TScan Therapeutics (TCRX) stake by 50% in Q3 2025, selling an estimated $25.7K and leaving 14,535 shares worth $26.5K. The position accounts for ﹤0.01% of the portfolio, ranked #661.

Point72 Asia (Singapore) first reported a position in TCRX in Q1 2024 and has held it in 3 quarters since. The position peaked at $157K in Q1 2024. 73 funds tracked by Wall St. Rank hold TCRX as of Q3 2025.

  • Point72 Asia (Singapore) held 14,535 shares of TScan Therapeutics worth $26.5K as of Q3 2025.
  • Point72 Asia (Singapore) sold 14,535 TScan Therapeutics shares in Q3 2025, an estimated $25.7K.
  • TScan Therapeutics made up ﹤0.01% of Point72 Asia (Singapore)'s portfolio in Q3 2025, its #661 holding.
  • Point72 Asia (Singapore) first reported a position in TScan Therapeutics in Q1 2024 and has held it in 3 quarters since.
  • Point72 Asia (Singapore)'s TScan Therapeutics position peaked at $157K in Q1 2024.
  • 73 funds tracked by Wall St. Rank held TScan Therapeutics as of Q3 2025.

Based on Point72 Asia (Singapore)'s 13F filing for Q3 2025, filed 14 Nov 2025.